Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.76 |
| ▸ | PGR | P06401 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.76 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | MLNR | O43193 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530974 | 0.98 | NR3C1 (0.80) | NR3C1PGRMAPTADORA3NR1I2 | |
| Butyric Acid SCHEMBL4899027 | 0.96 | NR3C1 (0.76) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL7271 | 0.94 | NR3C1 (0.78) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL20485505 | 0.94 | NR3C1 (0.78) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL4174889 | 0.94 | NR3C1 (0.77) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL11748332 | 0.94 | NR3C1 (0.84) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL29395436 | 0.94 | NR3C1 (0.84) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL509817 | 0.94 | NR3C1 (0.84) | NR3C1PGRMAPTADORA3NR1I2 | |
| Propionic Acid SCHEMBL8077640 | 0.93 | NR3C1 (0.78) | NR3C1PGRMAPTADORA3NR1I2 | |
| Betamethasone Dipropionate SCHEMBL15876389 | 0.92 | NR3C1 (0.88) | NR3C1PGRMAPTADORA3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170069-A1 | NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF | XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) | 2025-05-29 | — | — | US | claimed |
| CN-119638769-A | Preparation method and application of betamethasone butyrate propionate | 南京易腾药物研究院有限公司 | 2025-03-18 | — | — | CN | claimed |
| EP-4470532-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xiangya Hospital, Central South University (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-118662643-A | Application of hormone medicine composition in preparation of medicine for treating osteoarthritis | 中南大学湘雅医院 | 2024-09-20 | — | — | CN | claimed |
| CN-115569199-B | Pharmaceutical composition and preparation method and application thereof | 海勃(上海)医药科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| EP-3993715-B1 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | claimed |
| WO-2023160631-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中南大学湘雅医院 | 2023-08-31 | — | — | WO | claimed |
| CN-116098866-A | Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-12 | — | — | CN | claimed |
| CN-116077465-A | Nanometer preparation for joint pain relief, and preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| CN-116077669-A | Glucocorticoid nano-lipid carrier for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-10-13 | — | — | US | claimed |
| EP-2367796-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2011-09-28 | — | — | EP | claimed |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-08-11 | — | — | US | claimed |
| WO-2010072354-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-04-15 | — | — | US | claimed |
| EP-2121615-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | claimed |
| US-20090012051-A1 | EXTERNAL PREPARATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1810692-A1 | REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRA2A | NR3C1 200/4885PGR 3342/4885MAPT 3172/4885 |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | NR3C1 679/4885PGR 3405/4885MAPT 2409/4885 |
| US-20090012051-A1 | EXTERNAL PREPARATION | CYP4A11, CYP46A1, CYP11B2 | NR3C1 556/4885PGR 2297/4885MAPT 4259/4885 |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | NR3C1 679/4885PGR 3405/4885MAPT 2409/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | NR3C1 62/4885PGR 1575/4885MAPT 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.